Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

More information: William B Feldman et al, Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study, BMJ (2024).

Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched pairs of ...

Existing COVID-19 medications and the latest vaccine booster should be effective against it, Long said, since “it’s really sort of a remixing of variants already circulating.” Millions of ...

The patient lists were generated using searches to identify asthma patients without a diagnosis of COPD, who have SABA inhalers, but no ICS inhalers, on their repeat medication list. Data was gathered ...

Several major pharmaceutical companies, including Pfizer, Bristol Myers Squibb and Sanofi, are set to raise prices on more than 250 branded medications in the U.S. starting Jan. 1, 2025 ...

Opens in a new tab or window There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease ...

a once daily dry powder inhaler, in patients with chronic obstructive pulmonary disease (COPD) treated in routine clinical practice. Design New user cohort study. Setting Longitudinal commercial US ...

Triple therapy of an inhaled corticosteroid, long acting β 2-agonist (LABA), and long acting muscarinic antagonist (LAMA) is more effective in reducing the annual rate of exacerbations compared with ...